Post-earnings recap
Reported
Thu, Nov 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss per share of $0.38, but did not provide revenue figures or guidance for future quarters. The stock reacted slightly down by 0.12%, indicating that investors may have been looking for more clarity on financial expectations. The lack of guidance may lead to uncertainty among investors as the company continues to focus on its drug development pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to developing innovative treatments. There was no specific guidance or updates on financial expectations.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their pipeline of therapies.